Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk

High-quality dividend stocks frequently produce market-beating returns over the long term. Eli Lilly and Novo Nordisk are two blue-chip dividend stocks with rock-solid payouts and strong growth prospects.

2 Magnificent Dividend Stocks to Buy Right Now

Following the latest approval, Lilly's (LLY) Jardiance can access a target market that affects more than 35 million adults in the United States.

FDA Expands Lilly (LLY) Jardiance Label in Chronic Kidney Disease

The potential ripple effects of GLP-1 weight loss drugs like Ozempic and Wegovy are far-reaching. There could be reduced demand for junk food and increased demand for athletic brands.

The disruptive effect of weight loss drugs like Ozempic could have surprising impacts on the stock market. Here are potential winners and losers.

Advanced Micro Devices

Exxon Mobil

The so-called “Magnificent 7” stocks surged in 2023, contributing to a market rebound in an outsized manner. The stocks' presumed overrepresentation has investors considering other investments in their place.

David vs. Goliath: 3 Stocks Poised to Challenge the ‘Magnificent 7′

Ginkgo Bioworks Holdings

Recursion Pharmaceuticals

Biotech has long seemed to move slower than its fellow tech fields due to the complexity of biological systems and the difficulty of drug regulations. However, that precedent is set to change thanks to the growing implementation of artificial intelligence ( AI ), upending the field and bringing big changes to the industry.

Immunomics Stocks: 3 Ways to Play This Massive AI-Biotech Megatrend

After massive gains this year, Eli Lilly's stock has eclipsed many analysts' price targets. Still, the drugmaker has huge growth potential from its current product lineup.

Are Wall Street Analysts Wrong About Eli Lilly Stock?

Eli Lilly & Co. LLY, -3.42% and Boehringer Ingelheim said Friday that the U.S. Food and Drug Administration has approved their blockbuster drug Jardiance, already used for heart failure and diabetes, as a treatment for adults with chronic kidney disease. The agency approved the tablets to cut the risk of sustained decline in kidney function, end-stage kidney disease, cardiovascular death and hospitalization in adults with the condition, the companies said in a release.

Eli Lilly, Boehringer Ingelheim's Jardiance gets FDA approval for chronic kidney disease

Approval adds to the treatment options for the more than 35 million adults in the U.S. affected by chronic kidney disease (CKD) Jardiance® (empagliflozin) 10 mg tablets significantly reduced the risk of kidney disease progression and cardiovascular death in adults with CKD, as established in the EMPA-KIDNEY phase III trial EMPA-KIDNEY is the first SGLT2 inhibitor CKD trial to demonstrate a statistically significant reduction in the risk of first and recurrent hospitalization in adults with CKD RIDGEFIELD, Conn. and INDIANAPOLIS , Sept.

US FDA approves Jardiance® for the treatment of adults with chronic kidney disease

Eli Lilly & Co. LLY, -3.42% is best positioned to dominate the fast-growing U.S. market for obesity drugs into the 2030s, BMO Capital Markets analysts said in a report late Thursday. Although Novo Nordisk NVO, -3.63%, maker of Ozempic and Wegovy, is likely to maintain significant market share, Lilly has an edge with its breadth of effective products, including the oral orforglipron, injectable tirzepatide, and next-generation retatrutide, the analysts wrote.

Eli Lilly set to dominate obesity drug market into the next decade, analysts say

Constellation Energy Corp

Fair Isaac

First Solar

Lamb Weston Hlds

Marathon Petroleum

NVIDIA

Who says higher interest rates are bad for S&P 500 stocks? A select group is thriving even as the Federal Reserve hikes.

7 Stocks Soar More Than 90% Even As Fed Hikes Rates

Drug giant Eli Lilly stock reached the 20%-25% profit zone after an August breakaway gap amid Wall Street enthusiasm for weight loss drugs.

Drug Giant Eli Lilly Hits Profit Zone Amid Enthusiasm For Weight-Loss Drugs

Goldman Sachs

Ionis Pharma

Pinduoduo Inc - ADR

Peloton

T-Mobile US

Toast

While many retail investors are keen to discover which securities the big market players are snapping up, sometimes it's more telling to zero in on the stocks institutional traders are selling. Why? Because trading, for all its analytics, can be an emotional rollercoaster.

The 7 Most Hated Stocks by Institutional Traders

Eli Lilly stock has outperformed my previous expectations due to its solid execution and growth in the weight management market. Analysts anticipate a $100B weight-loss drugs market by 2030, with Lilly accounting for about $50B in sales. Questions must be asked whether the market has reflected significant optimism. Its "F" valuation grade cannot be ignored.

Eli Lilly: Don't Be Fooled By Greed

Eli Lilly & Co. (LLY) sued 10 medical spas, wellness centers, and compounding pharmacies across the U.S. for allegedly selling products that fraudulently claimed to be its popular diabetes drug, Mounjaro.

Eli Lilly Sues Businesses Over Alleged Sales of Fake Mounjaro Diabetes Drugs

Eli Lilly has taken legal action against spa owners, wellness centres and pharmacies for unauthorised versions of its best fat-busting drug Mounjaro. Four separate lawsuits have been filed against outlets selling products they claim contain tirzepatide, the active ingredient in Mounjaro.

Eli Lilly sues spas and pharmacies over bootlegged Mounjaro

AbbVie

Amgen

CRISPR Therapeutics

Johnson & Johnson

Molina Healthcare

Merck

Pfizer

Seagen

UnitedHealth Group

If you're looking for a sector that's on sale, look to healthcare. The Health Care Select Sector SPDR Fund NYSEARCA: XLV is down 2.50% in the past month, lagging the S&P 500.

Flee to Healthcare Stocks if Recession Rears its Head?

DexCom

West Pharmaceutical Services

DexCom, Eli Lilly, and West Pharmaceutical Services have been among the hottest healthcare stocks to own over the past decade. These top healthcare companies are in good positions to benefit from even more growth in the future.

3 Healthcare Stocks That Turned $100,000 Into $1 Million in 10 Years

The lawsuits come as Eli Lilly grapples with a shortage of Mounjaro in the U.S. due to skyrocketing demand.

Eli Lilly sues clinics allegedly selling knockoff versions of Mounjaro diabetes drug

Eli Lilly on Tuesday said it was suing 10 U.S. medical spas, wellness centers and compounding pharmacies for selling products claiming to contain tirzepatide, the active ingredient in its diabetes drug Mounjaro which is expected to be approved for weight loss later this year.

Eli Lilly sues over US sales of bogus Mounjaro for weight loss

SAN DIEGO--(BUSINESS WIRE)--Boundless Bio, a clinical stage, next-generation precision oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced a clinical trial collaboration and supply agreement with Eli Lilly and Company for supply of their CDK4/6 inhibitor Verzenio® (abemaciclib) for use in combination with BBI-355 in a clinical trial of patients with locally adv.

Boundless Bio Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate VERZENIO® (abemaciclib) in Combination with BBI-355 in Patients with CDK4 or CDK6 Amplified Solid Tumors

Pharmaceutical giant Eli Lilly & Co. NYSE: LLY stock has been on a tear, trading up 57.7% year-to-date (YTD). The company is firing on all cylinders with its leading medications and a highly anticipated pipeline of hopeful game-changing drugs.

Could Ely Lilly Be the Best Pharma Stock to Own Now and Forever?

Block

Block's fall after a decent earnings report shows that growth stocks and retailers are fighting an uphill battle against investor fears. Eli Lilly's move higher illustrates what it takes to break free from negative market sentiment.

2 Stocks That Moved the Market in August

Eli Lilly's stock has performed well in the market, boosted by strong fundamental results and the success of Novo Nordisk's weight loss drug, Wegovy. Wegovy demonstrated a 20% reduction in the risk of heart attack, stroke, or heart-related death in obese or overweight individuals with cardiovascular disease. The success of Wegovy could have positive implications for Eli Lilly's incretin drugs, tirzepatide and retatrutide, in the field of obesity treatment.

Eli Lilly: A Potential Game Changer For Weight Management And Cardiovascular Health

The biotech sector is notorious for its sky-high R&D costs, regulatory hurdles, and lengthy timelines to bring a drug to market. Stock Strategist Andrew Rocco unveils 3 biotech stocks that have broken through and are set up for long term growth.

"Blockbuster Status": 3 Bios to Buy and Hold

Centene

Fortinet

Halliburton

Intel

Phillips 66

Valero Energy

September is living up to its rap as the worst month of the year for the S&P 500. But investors are still finding stocks to make money on.

News for Eli Lilly Stock (LLY)